Abstract: A water-in-oil-in-water (W1/O/W2) emulsion comprising a lipid phase (O) and a water phase (W2), the lipid phase being distributed inside the water phase, wherein the lipid phase contains water droplets (W1), wherein the water content inside the lipid phase is between 10 wt % and 80 wt % relative to total weight of the lipid phase, wherein the water droplets are stabilized inside the lipid phase by an emulsifier composition, wherein the emulsifier composition comprises an Acetone-insoluble (AI) component containing a Phosphatidyl Choline (PC), a Phosphatidyl Inositol (PI), a Phosphatidyl Ethanolamine (PE) and a Phosphatidic Acid (PA), wherein PC is at most 15.5% relative to the total weight of the emulsifier composition and wherein the emulsifier composition has a phospholipid weight ratio R of at most 65%, the ratio R being defined according to Formula R(in %)=100×(PC+PI+PE+PA)/AI.

Abstract: There is provided a controlled-release antibiotic socket for securely holding an implantable medical device that is made from: at least one film having at least one polymer layer, where the at least one film is formed into the socket; at least one antibiotic agent; and at least one opening in the socket, where the at least one polymer layer comprises a biodegradable elastomeric polymeric material; and the at least one antibiotic agent is dispersed within at least one of the at least one polymer layers and/or, when the film comprises at least two polymer layers, the at least one antibiotic agent is disposed as a separate layer between two polymer layers. Also disclosed is the film used to make the socket and uses of both the socket and film.

Abstract: An orodispersible solid pharmaceutical dosage unit of estetrol is disclosed. The solid dosage unit is easy to manufacture and suited for sublingual, buccal or sublabial administration. The orodispersible solid pharmaceutical dosage unit can include at least 100 ?g of an estetrol component and pharmaceutically acceptable excipients. Methods of manufacturing the orodispersible solid pharmaceutical dosage unit are also disclosed.

Abstract: The present disclosure provides tissue products produced from adipose tissues, as well as methods for producing such tissue products. The tissue products can include acellular extracellular matrices. In addition, the present disclosure provides systems and methods for using such products.

Abstract: This invention provides for a thin emulsion base for cosmetic products with low to medium viscosity. The bases are excipients that provide stability to cosmetic products. The thin emulsion bases of this invention are from non-synthetic and non-petroleum based products and comprise over 80% juice derived solvents with the balance being a combination of alkane texture enhancers and lipid emulsifiers.

Abstract: The invention concerns a mixture or a composition, that is preferably therapeutically active by topical administration, comprising: —at least one metal salt, the metal being chosen from molybdenum (Mo), tungsten (V), vanadium (V), gold (Au), a lanthanide, in particular lanthanum; —at least one chelating agent; —at least one source of peroxidative radicals; —at least one buffer agent; and pharmaceutical compositions constituted by or comprising said mixture, the methods for producing same and applications thereof, in particular in a method for the therapeutic treatment of a viral infection, and in particular involving a virus of the Herpesviridae family; or as an anti-inflammatory.

Abstract: The present disclosure relates to use of Sodium 3,5-dichloro-2,4,6-trioxo-1,3,5-triazinan-1-ide having a chemical structure: for the treatment and/or prevention of COVID-19 infection. The present disclosure further relates to a pharmaceutical formulation that is administered in the form of dry powder inhalation (DPI) to the subject. The dry powder inhalation formulation comprises a micronized Sodium 3,5-dichloro-2,4,6-trioxo-1,3,5-triazinan-1-ide, a first lactose, a second lactose, and at least one excipient. The pharmaceutical formulation of the present disclosure increases the bioavailability of the NaDCC, has patient compliance, and reduced adverse effects.

Abstract: The invention relates to methods for treating or preventing infections with coronavirus, in aspects including Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), and SARS-CoV-2-induced COVID-19. The methods comprise administering a pharmaceutically acceptable composition comprising an effective amount of verapamil. In aspects, the composition is administered through pulmonary delivery. In aspects, the composition is administered through a nasal spray. Such methods modulate the entry and replication of coronavirus in host cells and effectively treat coronavirus infection.

Abstract: Single oral solid dosage form comprising an immediate release first dosage composition having at least two antibiotic agents and a delayed release second dosage composition having a proton pump inhibitor are provided herein. The single oral solid dosage form according to some aspects of the invention can be used for the treatment of disorders associated with infection by H. pylori or the prevention of recurrence of disorders associated with infection by H. pylori.

Abstract: Provided is a process for the production of nano- and/or microparticles containing a therapeutically active agent embedded in a polymer matrix or encapsulated by a polymer shell, and nano- and/or microparticles obtainable by the process, said process comprising the steps of: a) providing a solution of a polymer selected from polylactide, polyglycolide, and polyester copolymers comprising copolymerized units of lactic acid and/or glycolic acid in an organic solvent S1 having limited water solubility; b) providing a solution or dispersion of a therapeutically active agent in as solvent or mixture of organic solvents S2 comprising at least 50 vol.

Abstract: A water-in-oil type emulsified cosmetic has an unprecedented property wherein, by coming into contact with perspiration or water, the color development and the color uniformity are improved over the conditions immediately after application. The water-in-oil type emulsified cosmetic includes: (A) an organically modified clay mineral; (B) an oil phase thickener other than the (A) organically modified clay mineral; (C) a non-volatile liquid oil other than a silicone oil; (D) a silicone-based surfactant having an HLB of less than 8; and (E) a colorant; wherein a weight ratio defined by [(A)+(B)]/(C) is at least 0.04 and less than 0.68.

Abstract: The present invention relates to a composition for reshaping keratin fibers with heat, comprising: (a) at least one organic alkaline agent having a pKa value of from 8.0 to 13.5; and (b) at least one polymeric thickener, (c) at least one organic acidic agent having pKa value of less than 3.5, and/or (d) at least one alkaline agent; wherein the composition has a pH of from 8.0 to 12, preferably from 8.5 to 11.5, and more preferably from 9.0 to 11.0. The composition according to the present invention is preferably a cosmetic composition, for keratin fibers, such as hair, and can be used for a process for reshaping the keratin fibers with heat. The composition according to the present invention can provide the keratin fibers with a sufficient reshaping efficiency such as strong wave intensity of the curled keratin fibers and good usability.

Abstract: The present invention is directed to a hemostatic material comprising a compacted, hemostatic aggregates of cellulosic fibers. In some aspects, the hemostatic material further includes additives, such as carboxymethyl cellulose (CMC) or other polysaccharides, calcium salts, anti-infective agents, hemostasis promoting agents, gelatin, collagen, or combinations thereof. In another aspect, the present invention is directed to a method of making the hemostatic materials described above by compacting a cellulosic-based material into hemostatic aggregates. In another aspect, the present invention is directed to a method of treating a wound by applying hemostatic materials described above onto and/or into the wound of a patient.

Abstract: A method of treating an individual infected with COVID-19, the method comprising the steps of: providing an individual infected with COVID-19; and administering five antimicrobials to the individual, wherein the antimicrobials comprise: hydroxychloroquine; azithromycin; vitamin C; vitamin D; and zinc.

Abstract: The present invention relates to a veterinary or pharmaceutical composition comprising: (i) about 1-65% w/v of a pyrethroid, or a salt thereof, (ii) a macrocyclic lactone, or a salt thereof, (iii) at least one alkalizing agent, (iv) at least one non aqueous solvent, wherein the pH of the composition is comprised between about 6.5 and 8.5, when measured by adding 25% of water to an aliquot of said composition. The invention further relates to the use of such composition for preventing and/or treating parasites infestations.

Abstract: A nasal spray formulation and a method of using a locally acting sodium channel blocker to treat pain is disclosed, wherein the nasal spray formulation comprises from about 5% to about 30% w/v of a locally active sodium channel blocker, from about 0.25% to about 5% w/v of a buffering agent, and from about 5 to about 99% w/v of a pharmaceutically acceptable carrier for nasal administration. The nasal spray formulation is preferably contained in a mechanical multi-dose pump which sprays a unit dose of the nasal spray formulation with a wide plume and small droplet size, such that the unit dose is administered by actuating the mechanical multi-dose spray pump device and spraying a volume of the nasal spray formulation into each nostril of a human subject. Preferably, the nasal spray formulation does not include a preservative.

Abstract: This disclosure provides bioceramic compositions of multiparticulate crystalline multimetallic silicates having silica double tetrahedra structures, such as Strontium-akermanite (Sr2MgSi2O7), Akermanite (Ca2MgSi2O7), Baghdadite (Ca3ZrSi2O9), Hardystonite (Ca2ZnSi2O7), as sources for controlled release of multiple metallic ions, such as Ca2+, Mg2+, Zr4+, Sr2+, Zn2+ for medical and dental use. This disclosure also includes medical and dental uses of the disclosed compositions, for example, in tissue regeneration, including bone tissue.

Abstract: Matrix particles containing one or more matrix materials and one or more hydrophobic active agents, agglomerated particles made therefrom, fibrous structures containing such matrix particles and/or agglomerated particles, and processes for making same are provided.

Abstract: Disclosed is a topical composition comprising: (i) an antimicrobial active which is at least one of piroctone, caprylhydroxamic acid, benzohydroxamic acid, or piroctone olamine; and (ii) norbraylin. Also disclosed is a non-therapeutic method of providing topical antimicrobial benefit on a topical surface of a human or animal body comprising a step of applying a safe and effective amount of the topical composition.

Abstract: The disclosure provides for solid products configured for oral use, the products including a carrier material; a releasable material; and wherein the releasable material is combined with the carrier material such that the releasable material is configured for sustained release from the solid product when the solid product is positioned in an oral cavity for a consumer. In another aspect, the disclosure provides for a method of preparing a solid product for oral use, the method comprising providing a releasable material in sprayable form; providing a pouch formed of a fibrous material; and spraying a flavor component onto a least a portion of the pouch one or both of before and after filling the pouch with the oral composition.